

DAFTAR PUSTAKA

1. World Health Organization. Global Tuberculosis Report 2024. 2024.
2. World Health Organization. Global Tuberculosis Report 2023. 2023.
3. Kemenkes RI. Profil Kesehatan Indonesia 2023. Kementerian Kesehatan Republik Indonesia; 2024.
4. Dinas Kesehatan Kota Padang. Profil Kesehatan Kota Padang Tahun 2022. Padang; 2023.
5. Lee JY. Diagnosis and Treatment of Extrapulmonary Tuberculosis. *Tuberc Respir Dis (Seoul)*. 2015;78:47. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC4388900/>
6. Sharma SK, Mohan A, Kohli M. Extrapulmonary Tuberculosis. *Expert Rev Respir Med*. 2021;15:931–48. Available from: <https://pubmed.ncbi.nlm.nih.gov/33966561/>
7. Sivaratnam L, Nawati A, Abdul Manaf M. An Evidence-Based Clinical Pathway for The Diagnosis of Tuberculous Lymphadenitis. *Int J Mycobacteriol*. 2020;9:107–15. Available from: https://journals.lww.com/ijmy/fulltext/2020/09020/an_evidence_based_clinical_pathway_for_the.1.aspx
8. Lemus LF, Revelo E. Cervical Tuberculous Lymphadenitis. *Cureus*. 2022;14:e31282. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9732912/>
9. Saidah R, Medina H. Karakteristik Pasien Limfadenitis Tuberkulosis di Kota Medan Tahun 2019. *Jurnal Ilmiah Maksitek*. 2021;6:317–9. Available from: <https://makarioz.sciencemakarioz.org/index.php/JIM/article/view/286>
10. Lugiana HR, Djannah F, Ajmala IE. Hubungan Antara Gambaran Sitologis dengan Metode FNAB dan Respon Terapi pada Pasien Limfadenitis Tuberkulosis di RSUD Provinsi NTB pada Tahun 2019. *Jurnal Kedokteran Unram*. 2021;10:521–6.
11. Hamzah F, Wiriansya EP, Takahasi TF, Tabri NA, Abdi DA. Karakteristik Pasien dengan Limfadenitis Tuberkulosis di RS Ibnu Sina Makassar Periode 2018 hingga 2022. *Jurnal Kesehatan Masyarakat*. 2024;8:3073–85. Available from: <https://journal.universitaspahlawan.ac.id/index.php/prepotif/article/view/29895>
12. Widiyastuti E, Ismawati I, Rachmawati M. Gambaran Klinis dan Histopatologis Pasien Limfadenopati Granulomatosa yang Berobat di Rumah Sakit Muhammadiyah Bandung. *Jurnal Integrasi Kesehatan & Sains*. 2024;6:71–6.

13. Kumbi H, Reda DY, Solomon M, Teklehaimanot A, Ormago MD, Ali MM. Magnitude of Tuberculosis Lymphadenitis, Risk factors, and Rifampicin Resistance at Adama city, Ethiopia: A Cross-Sectional Study. *Sci Rep*. 2023;13:1–8.
14. Shetty D, Vyas D. Combination Method for The Diagnosis of Tuberculous lymphadenitis in High Burden Settings. *Surgical and Experimental Pathology*. 2022;5:11. Available from: <https://doi.org/10.1186/s42047-022-00111-z>
15. Istiharo TR, Djannah F, Ajmala IE. Hubungan Antara Gambaran Sitologi Menggunakan Metode FNAB dengan Respon Terapi pada Pasien Limfadenitis Tuberkulosis di Pulau Lombok. *Jurnal Kedokteran Unram*. 2022;11:1169–75.
16. Nabila Silviani Hendarsah, Nita Sahara, Neno Fitriyani Hasbie, Eko Purnanto. Hubungan Gambaran Klinis dengan Pemeriksaan Sitopatologi Metode FNAB pada Pasien Limfadenitis TB di RSUD Dr.H. Abdul Moeloek Lampung. *Jurnal Ilmu Kedokteran dan Kesehatan*. 2023;10:2483–91.
17. Algarni A, Alansari N, Alqurashi M, Alsaeed M. Clinical Characteristics and Outcome of Tuberculosis lymphadenitis in a Tertiary Center From Saudi Arabia. *J Clin Tuberc Other Mycobact Dis*. 2023;33:100384. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC10727992/>
18. Damor P, Thakor N, Baranda U, Gadhavi R, Patel N, Thakkar D, et al. Human Immunodeficiency Virus Associated Tuberculous Lymphadenitis: A Clinical Study of 50 Cases of Saurashtra Region of Gujarat, India. *International Journal of Advances in Medicine*. 2015;2:100.
19. Huda MM, Taufiq M, Yusuf MA, Rahman MR, Begum F, Kamal M. Clinico-Demographic Characteristics of Tuberculous Lymphadenitis: Experience of 50 Cases in Bangladesh. *J Tuberc Res*. 2016;4:220–6.
20. Azizi FH, Husin UA, Rusmartini T. Gambaran Karakteristik TB Paru dan Ekstra Paru di BBKPM Bandung Tahun 2014. *Prosiding Pendidikan Dokter*. 2015;859–66.
21. Bayraktar B, Bulut E, Bariş AB, Toksoy B, Dalgic N, Celikkan C, et al. Species Distribution of the Mycobacterium Tuberculosis Complex in Clinical Isolates from 2007 to 2010 in Turkey: a Prospective Study. *J Clin Microbiol*. 2011;49:3837. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC3209075/>
22. Stoller J. Murray & Nadel's Textbook of Respiratory Medicine, 6th Edition. Vol. 12, Annals of the American Thoracic Society. 2016. 539–628 p.
23. Palange P, Rohde G. Handbook Respiratory Medicine 3rd Edition. 2019.

24. Jackson M. The Mycobacterial Cell Envelope—Lipids. *Cold Spring Harb Perspect Med.* 2014;4:a021105. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC4200213/>
25. Srinivas CV, Nair S. Clinicopathological Profile of Cervical Tubercular Lymphadenitis with Special Reference to Fine Needle Aspiration Cytology. *Indian Journal of Otolaryngology and Head & Neck Surgery.* 2017;71:205. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6848329/>
26. Ferry JA. Infectious Lymphadenitis. *Diagnostic Pathology of Infectious Disease.* 2017;323–51.
27. Highsmith HY, Starke JR, Mandalakas AM. Tuberculosis. *Kendig's Disorders of the Respiratory Tract in Children.* 2019;475-497.e5.
28. Dasgupta S, Chakrabarti S, Sarkar S. Shifting Trend of Tubercular Lymphadenitis Over A Decade – A Study From Eastern Region of India. *Biomed J.* 2017;40:284. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6138605/>
29. Pajor AM, Józefowicz-Korczyńska M, Korzeniewska-Kosela M, Kwiatkowska S. A Clinic-Epidemiological Study of Head and Neck Tuberculosis — A Single-Center Experience. *Adv Respir Med.* 2016;84:324–30.
30. Hegde S, Rithesh KB, Baroudi K, Umar D. Tuberculous Lymphadenitis: Early Diagnosis and Intervention. *J Int Oral Health.* 2014;6:96. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC4295467/>
31. Karleen C, Saniasiaya J. Cervical Tuberculous Lymphadenitis. Vol. 14, *BMJ Case Reports.* BMJ Publishing Group; 2021.
32. Perhimpunan Dokter Paru Indonesia (PDPI). *Pedoman Diagnosis dan Penatalaksanaan Tuberkulosis di Indonesia.* 2nd ed. Jakarta; 2021.
33. Kemenkes RI. *Pedoman Nasional Pelayanan Kedokteran Tatalaksana Tuberkulosis.* Vol. 6. 2020.
34. Hendarsah N, Sahara N, Hasbie N, Purnanto E. Hubungan Gambaran Klinis dengan Pemeriksaan Sitopatologi Metode FNAB pada Pasien Limfadenitis TB di RSUD Dr. H. Abdul Moeloek Lampung. *Jurnal Ilmu Kedokteran dan Kesehatan.* 2023;10:2483–91.
35. Fadhilla H, Sudarmanto S. Seorang Anak Perempuan Usia 4 Tahun dengan Benjolan pada Leher Kanan. *Proceeding Book Call for Papers Fakultas Kedokteran Universitas Muhammadiyah Surakarta.* 2024;355–61.
36. Liu Q, Li W, Chen Y, Du X, Wang C, Liang B, et al. Performance of Interferon-Release Assay in The Diagnosis of Tuberculous Lymphadenitis: A

Meta-Analysis. PeerJ. 2017;2017:e3136. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC5391793/>

37. Jadhav DS, Deshmukh VV, Mahato NH, Valand AG. Comparative Study of Ziehl-Neelsen Stain Versus Fluorescent Microscopy in Diagnosis of Tuberculous Lymphadenitis on FNAC at a Tertiary Care Centre. 2019; Available from: www.medresearch.in
38. Kumbi H, Ali MM, Abate A. Performance of Fine Needle Aspiration Cytology and Ziehl-Neelsen Staining Technique in The Diagnosis of Tuberculosis Lymphadenitis. BMC Infect Dis. 2024;24:633. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC11197254/>
39. Kant K, Baveja CP, Sarkar J, Juyal D. Microbiological Evaluation of Clinically Suspected Cases of Tubercular Lymphadenopathy By Cytology, Culture, and Smear Microscopy – A Hospital-Based Study from Northern India. J Family Med Prim Care. 2019;8:828. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6482784/>
40. World Health Organization. WHO Consolidated Guidelines on Tuberculosis Module 3 : Diagnosis Rapid Diagnostics for Tuberculosis Detection Third Edition. 2024.
41. Mukhida S, Vyawahare CR, Mirza SB, Gandham NR, Khan S, Kannuri S, et al. Role of GeneXpert MTB/RIF Assay for The Diagnosis of Cervical Lymph Node Tuberculosis And Rifampicin Resistance. Tzu-Chi Medical Journal. 2022;34:418. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9791852/>
42. Nagalakshmi V, Nagabhushana D, Aara A. Primary Tuberculous Lymphadenitis: A Case Report. Clin Cosmet Investig Dent. 2010;2:21. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC3645454/>
43. Song I, Jeong YJ, Lee KS, Koh WJ, Um SW, Kim TS. Tuberculous Lymphadenitis of The Thorax: Comparisons of Imaging Findings Between Patients With and Those Without HIV Infection. American Journal of Roentgenology. 2012;199:1234–40. Available from: <https://ajronline.org/doi/10.2214/AJR.12.8522>
44. Arul P, Masilamani S, Akshatha C. Diagnostic Efficacy of Fine-Needle Aspiration Cytology in the Evaluation of Cervical Lymphadenopathy. Journal of the Scientific Society. 2016;43:117.
45. Eshete A, Zeyinudin A, Ali S, Abera S, Mohammed M. M. Tuberculosis in Lymph Node Biopsy Paraffin-Embedded Sections. Tuberc Res Treat. 2011;2011:127817. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC3335535/>

46. Sahara N, Marciano R. Hubungan Morfologi Klinis dengan Diagnosis Sitopatologi Metode Fine Needle Aspiration Biopsy (FNAB) pada Pasien Limfadenitis Tuberkulosis di Rumah Sakit Abdul Moeloek. *Jurnal Ilmu Kedokteran dan Kesehatan*. 2023;10:2023. Available from: <http://ejournalmalahayati.ac.id/index.php/kesehatan>
47. Hemalatha A, Shruti P, Kumar MU, Bhaskaran A. Cytomorphological Patterns of Tubercular Lymphadenitis Revisited. *Ann Med Health Sci Res*. 2014;4:393. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC4071740/>
48. World Health Organization. WHO Consolidated Guidelines on Tuberculosis Module 4: Treatment Drug-Susceptible Tuberculosis Treatment. 2022.
49. World Health Organization. WHO Consolidated Guidelines on Tuberculosis Module 5: Management of Tuberculosis in Children and Adolescents. 2022.
50. Lekhbal A, Chaker K, Halily S, Abada RL, Rouadi S, Roubal M, et al. Treatment of Cervical Lymph Node Tuberculosis: When Surgery Should be Performed? a Retrospective Cohort Study. *Annals of Medicine and Surgery*. 2020;55:159. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC7256428/>
51. Kumbi H. Magnitude of Tuberculosis Lymphadenitis, Risk Factors, and Rifampicin Resistance at Adama City, Ethiopia: a Cross-Sectional Study. *National Library of Medicine*. 2023. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518321/>
52. Depkes RI. Profil Kesehatan Indonesia. Jakarta: Depkes RI. 2009;200.
53. World Health Organization. The Asia-Pacific Perspective - Redefining Obesity and Its Treatment. 2002. 17–18 p.
54. Mulyani Henni, Asri Aswiyanti. Gambaran Limfadenitis Tuberkulosis Pada Anak yang Didiagnosis dengan FNAB di Bagian Patologi Anatomi Fk Unand-RSUP Dr.M. Djamil, Padang. 2009.
55. Shodikin MA, Ayu PP, Handoko A. Hubungan Riwayat Tuberkulosis Paru pada Keluarga dengan Terjadinya Limfadenitis Tuberkulosis pada Anak. *Jurnal Kesehatan Masyarakat Indonesia*. 2021;16:168–76. Available from: <https://jurnal.unimus.ac.id/index.php/jkmi>,
56. Purbaningsih W, Rachmawati M, Triyani Y, Rahmi FS. Histopathological Review of Granuloma in Diagnosis of Tuberculosis Lymphadenitis (TBL). *Global Medical & Health Communication (GMHC)*. 2023;11:171–5.
57. Febrian MA. Faktor-Faktor yang Berhubungan dengan Kejadian TB Paru Anak di Wilayah Puskesmas Garuda Kota Bandung. *Jurnal Ilmu Keperawatan Universitas BSI*. 2015;III:64–79.

58. Apriliasari R, Hestningsih R, Udiyono Peminatan Epidemiologi dan Penyakit Tropik Fakultas Kesehatan A. Faktor yang Berhubungan dengan Kejadian TB Paru pada Anak (Studi di Seluruh Puskesmas di Kabupaten Magelang). Vol. 6. 2018 Jan. Available from: <http://ejournal3.undip.ac.id/index.php/jkm>
59. Rusmini H, Ariza R, Rahayu N, Sari P. Characteristics Of Lymphadenitis in Hospitalised Patients Bandar–Lampung, Indonesia. Vol. 02, Malahayati International Journal of Nursing and Health Science. 2019 Mar.
60. Alfaridzi M, Lestarini IA, Djannah F. Hubungan Gambaran Histopatologi dengan Jumlah Leukosit pada Penderita Limfadenitis Tuberkulosis di Nusa Tenggara Barat Tahun 2019. *Jurnal Kedokteran*. 2021;10:405–12.
61. Gupta M, Srikrishna G, Klein SL, Bishai WR. Genetic and Hormonal Mechanisms Underlying Sex-Specific Immune Responses in Tuberculosis. *Trends Immunol*. 2022;43:640–56.
62. Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Möller M. The X Chromosome and Sex-Specific Effects in Infectious Disease Susceptibility. *Hum Genomics*. 2019;13:1.
63. Carranza C, Carreto-Binaghi LE, Guzmán-Beltrán S, Muñoz-Torrico M, Torres M, González Y, et al. Sex-Dependent Differential Expression of Lipidic Mediators Associated with Inflammation Resolution in Patients with Pulmonary Tuberculosis. *Biomolecules*. 2022;12:1–6.
64. Haerunnisya PU, Wiriansya P, Musa IM, Yanti KE, Irsansady F. Karakteristik Penderita Penyakit Tuberkulosis Ekstra Paru di Balai Besar Kesehatan Paru Masyarakat dan RS Ibnu Sina Makassar Tahun 2018 - 2022. *Jurnal Kesehatan Masyarakat*. 2024;8:234–41.
65. Nhamoyebonde S, Leslie A. Biological Differences Between The Sexes and Susceptibility to Tuberculosis. *Journal of Infectious Diseases*. 2014;209. Available from: <https://pubmed.ncbi.nlm.nih.gov/24966189/>
66. Buttle TS, Hummerstone CY, Billahalli T, Ward RJB, Barnes KE, Marshall NJ, et al. The Monocyte-to-Lymphocyte Ratio: Sex-Specific Differences in The Tuberculosis Disease Spectrum, Diagnostic Indices and Defining Normal Ranges. *PLoS One*. 2021;16. Available from: <https://pubmed.ncbi.nlm.nih.gov/34460817/>
67. Fitriana E, Simanjuntak JP, Hermansyah H, Kesehatan P, Palembang KK, Id EA. Analisis Kadar Interferon Gamma pada Penderita TB. *Journal of Telenursing (JOTING)*. 2024;6:2496–502. Available from: <https://doi.org/10.31539/joting.v6i2.12990>
68. TVRI Sumatera Barat. Hingga Juni 2024, Tercatat Sebanyak 2.122 Kasus TBC di Kota Padang - Berita TVRI Stasiun Sumatera Barat. TVRI Sumatera Barat. 2024. Available from: <https://www.tvrisumbar.co.id/berita/detil/>

7646/hingga-juni-2024%2C-tercatat-sebanyak-2.122-kasus-tbc-di-kota-pada
ng.html

69. Antara Sumbar. Dinkes Pesisir Selatan Temukan 1.076 Kasus TBC pada 2024 -ANTARA Sumbar. AntaraNEWS. 2024. Available from: <https://sumbar.antaranews.com/berita/648154/dinkes-pesisir-selatan-temukan-1076-kasus-tbc-pada-2024>
70. BPSP Sumatera Barat. Kasus Penyakit Menurut Kabupaten/Kota dan Jenis Penyakit di Provinsi Sumatera Barat, 2024 - Tabel Statistik - Badan Pusat Statistik Provinsi Sumatera Barat. BPSP Sumatera Barat. 2025. Available from: <https://sumbar.bps.go.id/id/statistics-table/3/YTA1Q1ptRmhUMEpXWTBsQmQyZzBjVzgwUzB4aVp6MDkjMw==/kasus-penyakit-menurut-kabupaten-kota-dan-jenis-penyakit-di-provinsi-sumatera-barat--2024.html>
71. Kubiak RW, Sarkar S, Horsburgh CR, Roy G, Kratz M, Reshma A, et al. Interaction of Nutritional Status and Diabetes on Active and Latent Tuberculosis: A Cross-Sectional Analysis. *BMC Infect Dis.* 2019;19. Available from: <https://pubmed.ncbi.nlm.nih.gov/31311495/>
72. Prince L, Andrews JR, Basu S, Goldhaber-Fiebert JD. Risk of Self-Reported Symptoms or Diagnosis of Active Tuberculosis in Relationship to Low Body Mass Index, Diabetes and Their Co-Occurrence. *Tropical Medicine and International Health.* 2016;21:1272–81. Available from: <https://pubmed.ncbi.nlm.nih.gov/27495971/>
73. Diriba G, Kebede A, Tola HH, Alemu A, Yenew B, Moga S, et al. Utility of Line Probe Assay in Detecting Drug Resistance and The Associated Mutations in Patients with Extrapulmonary Tuberculosis in Addis Ababa, Ethiopia. *SAGE Open Med.* 2022;10:1.
74. Sharma SK, Mohan A. Extrapulmonary Tuberculosis. *Indian J Med Res.* 2004;120:316–53. Available from: <https://pubmed.ncbi.nlm.nih.gov/15520485/>
75. Kathamuthu GR, Moideen K, Baskaran D, Banurekha V V., Nair D, Sekar G, et al. Tuberculous Lymphadenitis Is Associated with Enhanced Baseline and Antigen-Specific Induction of Type 1 and Type 17 Cytokines and Reduced Interleukin-1 β (IL-1 β) and IL-18 at the Site of Infection. *Clin Vaccine Immunol.* 2017;24:e00045-17. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC5424238/>
76. Fontanilla JM, Barnes A, Von Reyn CF. Current Diagnosis and Management of Peripheral Tuberculous Lymphadenitis. *Clinical Infectious Diseases.* 2011;53:555–62. Available from: <https://pubmed.ncbi.nlm.nih.gov/21865192/>

77. Patel K. A Clinical Study of Tuberculous Cervical Lymphadenopathy: Surgeon's Perspectives. *International Surgery Journal*. 2019;6:581–5.
78. Salvador F, Los-Arcos I, Sánchez-Montalvá A, Tórtola T, Curran A, Villar A, et al. Epidemiology and Diagnosis of Tuberculous Lymphadenitis in a Tuberculosis Low-Burden Country. *Medicine (United States)*. 2015;94:1–6.
79. Öztomurcuk D, Terzi Ö, Demirci C, Kılıçaslan Z. Investigation of Granulomatous Inflammations in Terms of Tuberculosis Diagnosis: A 5-Year Multi-center Laboratory Study. *Turk Thorac J*. 2022;23:11–6.
80. Kusuma Atmaja H, Dramawan A, Keperawatan Poltekkes Kemenkes Mataram J, Kesehatan J V. Analisa Faktor-Faktor Penyebab Masalah Putus Obat pada Program Kontrol Tuberkulosis di Wilayah Kerja Puskesmas Gerung Lombok Barat. *Jurnal Kesehatan Prima*. 2014;8:1345–54.
81. Frans FB, Sitompul M. Pengaruh Pengawas Menelan Obat terhadap Kepatuhan Penderita TB Paru dalam Menelan Obat. *MAHESA : Malahayati Health Student Journal*. 2023;3:2189–200.
82. Vega V, Cabrera-Sanchez J, Rodríguez S, Verdonck K, Seas C, Otero L, et al. Risk Factors for Pulmonary Tuberculosis Recurrence, Relapse and Reinfection: A Systematic Review and Meta-Analysis. *BMJ Open Respir Res*. 2024;11:1–10.

